# Persistent and Debilitating Muscle Spasms | Utah Medical Cannabis Guidelines > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/spasticity-clinical-guidelines-cannabis-utah/ > **Published:** 2026-04-05T10:25:12-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:30:15-04:00 > **Clinical Summary:** Explore Utah's spasticity clinical guidelines for medical cannabis use in persistent muscle spasms, offering evidence-based dosing and treatment protocols. --- ✦ New CED Clinical Relevance  #76Notable Clinical Interest  Emerging findings or policy developments worth monitoring closely. ⚒ Cannabis News  |  CED Clinic SpasticityClinical GuidelinesMultiple SclerosisDosing Protocols[State Policy](https://cedclinic.com/will-the-coronavirus-force-states-to-legalize-marijuana/) Why This Matters Utah’s evidence-based guidelines represent a significant step toward standardized clinical protocols for cannabis in spasticity management. This addresses a critical gap where clinicians have limited guidance on dosing, delivery methods, and monitoring for muscle spasm conditions. Clinical Summary Utah has published clinical guidelines for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) use in persistent and debilitating muscle spasms, likely covering conditions such as multiple sclerosis, spinal cord injury, and cerebral palsy. The guidelines appear to provide evidence-based recommendations for cannabis formulations, dosing protocols, and clinical monitoring. This represents part of Utah’s broader effort to establish medical standards for their regulated cannabis program, moving beyond simple qualifying condition lists toward actionable clinical protocols. Dr. Caplan’s Take “Having clear, state-endorsed protocols is invaluable for clinicians who’ve been navigating spasticity treatment with cannabis largely on clinical intuition. This type of guidance helps legitimize and standardize what many of us have been doing empirically for years.” Clinical Perspective 🧠 Clinicians treating spasticity should review these guidelines as a framework for systematic cannabis implementation, particularly for dosing initiation and titration schedules. Patients with qualifying spastic conditions may benefit from discussing these standardized approaches with their providers rather than relying on dispensary recommendations alone. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Persistent%20and%20debilitating%20muscle%20spasms%20%7C%20Center%20for%20Medical%20Cannabis%20-%20Utah.g...%20%40drcaplan&url=https%3A//medicalcannabis.utah.gov/evidence-based-guidelines/persistent-and-debilitating-muscle-spasms/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//medicalcannabis.utah.gov/evidence-based-guidelines/persistent-and-debilitating-muscle-spasms/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Persistent%20and%20debilitating%20muscle%20spasms%20%7C%20Center%20for%20Medical%20Cannabis%20-%20Utah.g...%20--%20via%20%40drcaplan.bsky.social%20https%3A//medicalcannabis.utah.gov/evidence-based-guidelines/persistent-and-debilitating-muscle-spasms/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://medicalcannabis.utah.gov/evidence-based-guidelines/persistent-and-debilitating-muscle-spasms/](https://medicalcannabis.utah.gov/evidence-based-guidelines/persistent-and-debilitating-muscle-spasms/) Table of Contents - [FAQ](#FAQ)[What is this clinical relevance rating about?](#What_is_this_clinical_relevance_rating_about) - [What medical condition is the focus of this update?](#What_medical_condition_is_the_focus_of_this_update) - [What type of clinical information is being presented?](#What_type_of_clinical_information_is_being_presented) - [Who would benefit from this clinical information?](#Who_would_benefit_from_this_clinical_information) - [Why is this considered notable clinical interest?](#Why_is_this_considered_notable_clinical_interest) - [Related](#Related) ## FAQ #### What is this clinical relevance rating about? This is CED Clinical Relevance #76, rated as “Notable Clinical Interest.” It indicates emerging findings or policy developments in [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) that are worth monitoring closely by healthcare professionals. #### What medical condition is the focus of this update? The primary focus is on spasticity, particularly in the context of multiple sclerosis. This represents an important area where cannabis-based medicines have shown therapeutic potential. #### What type of clinical information is being presented? This update covers clinical guidelines and dosing protocols for cannabis treatment. These guidelines help healthcare providers make evidence-based decisions about [cannabis therapy](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/) for appropriate patients. #### Who would benefit from this clinical information? Healthcare providers treating patients with multiple sclerosis and spasticity would find this most relevant. It’s particularly useful for clinicians considering or currently prescribing [cannabis-based treatments](https://cedclinic.com/cannabis-medical-clinic-experience-beyond-smoking-vaping/). #### Why is this considered notable clinical interest? Cannabis treatment for spasticity represents an evolving area of medicine with developing evidence base. New guidelines and dosing protocols help standardize care and improve patient outcomes in this emerging therapeutic area. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Evidence based guidelines | Center for Medical Cannabis | Utah Department of Health and …](https://cedclinic.com/2026-cannabis-clinical-guidelines-utah-medical-cannabis/) Learn more about Utah's comprehensive evidence-based guidelines for [medical cannabis](https://cedclinic.com/therapeutic-benefits-of-thc/) use across various conditions. [Read Guidelines](https://cedclinic.com/2026-cannabis-clinical-guidelines-utah-medical-cannabis/) [Medical Cannabis Significantly Reduced Use of Opioids and Other Rx Drugs](https://cedclinic.com/medical-cannabis-opioid-alternatives-reduce-rx-drug-use/) Explore research showing how medical cannabis can reduce reliance on opioids and prescription medications. [Explore Research](https://cedclinic.com/medical-cannabis-opioid-alternatives-reduce-rx-drug-use/) [Medical marijuana rescheduling is legally puzzling but still a ‘huge win’ for patients](https://cedclinic.com/medical-cannabis-rescheduling-legal-shift-patient-impact/) Understand the legal landscape changes around medical marijuana and their impact on patient access and care. [Learn More](https://cedclinic.com/medical-cannabis-rescheduling-legal-shift-patient-impact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).